
When Paul Hudson, a British national, took over at the helm of French pharmaceutical company Sanofi back in June 2019, it was said that multi-blockbuster Dupixent could reach top sales of USD 11bn.
Since then, the drug has continued its explosive growth, and Sanofi is now lifting its sales ambitions for Dupixent to as much as USD 14.5bn, the company has announced in a press release ahead of an immunology investor event today, Tuesday, March 29.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app